Close Menu

NEW YORK (GenomeWeb) – Veracyte announced after the close of the market on Monday that its fourth quarter revenues grew 32 percent year over year and beat the consensus Wall Street estimate.

For the three months ended Dec. 31, 2018, the South San Francisco, California-based genomics diagnostics firm posed $25.8 million in revenues, up from $19.6 million in Q4 2017 and above analysts' average estimate of $24.4 million.

Total genomic test volume was up 28 percent year over year to 9,154 tests in the quarter, Veracyte said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.